×

Neville Registrars is delighted to welcome Consolidated Growth Holdings Limited as the newest addition to its list of client companies.

Information on Consolidated Growth Holdings can be found on the Company website: http://www.cgh-limited.com/

Close

×

RNS Number : 5698I

EU Supply PLC

22 March 2018

 

22 March 2018

EU Supply plc

("EU Supply", the "Company" or the "Group")

 

Contract Win Denmark

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that the Group has been awarded a contract by the Danish Competition and Consumer Authority ("Authority") for delivery of CTMTM as SaaS and related services to the Authority. There is also an option for up to 6 other authorities in Denmark within the Ministry of Industry, Business and Financial Affairs to join the contract.

 

 

FURTHER ENQUIRIES

EU Supply PLC Tel: 020 7127 4545 Thomas Beergrehn, CEO   Fredrik Wallmark, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, Ed Thomas

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for esourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 8,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRASEUSAEFASEED

Close

×

Neville Registrars is delighted to welcome Bellzone Mining plc as the newest addition to its list of client companies.

Bellzone Mining is an emerging iron ore and nickel exploration and development Company operating in the Republic of Guinea, West Africa.

Further information can be found on the Company's website: http://www.bellzone.com/

Close

×

Neville Registrars is delighted to welcome First Sentinel Plc as the newest addition to its list of client companies.

First Sentinel is an alternative investment company, registered with the FCA as a small authorised UK AIFM, which provides growth capital for public and private company investments. First Sentinel PLC invests in a range of debt and equity instruments in target portfolio companies.

Further information can be found on the Company's website: https://first-sentinel.com/

Close

×

RNS Number : 0433H

Concepta PLC

08 March 2018

 

8 March 2018

Concepta plc

("Concepta" or the "Company")

 

myLotus obtains Ethics Committee approval to commence trial in UK

Concepta plc (AIM: CPT) the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce that it has received Ethics Committee* approval to commence the user trial for its myLotus product in the UK.

Concepta has engaged the renowned UK-based company, The Clinical Trial Company, which specialises in clinical studies for pharmaceutical, biotechnology and medical device companies to manage the trial, which will be conducted in Rhyl, UK.

The trial is expected to commence in the next month, with 120 women testing the device for ease of use and clarity of instructions. Patient recruitment for the trial, the process of testing, collecting samples, reporting, result analysis and the final report is expected to take approximately four months. The results will be included alongside those of the stability trials1 and the technical file2 to support the Company's CE-mark.

Concepta also announces that the myLotus product format and the labelling for EU markets has been finalised and it is currently waiting to undergo the strict audit process of the Company's Notified Body: BSI. The audit is expected to be carried out upon completion of the trial in order to obtain final CE-marking.

Erik Henau, CEO of Concepta commented: "We are delighted to announce this important milestone. Over the last few months, we have dedicated considerable effort to meet the necessary requirements and regulations in order to expedite our CE-marking process. We look forward to obtaining this key certification in the coming months, which will allow us to launch our myLotus product in our initial target European markets of the UK, and subsequently, other EU markets as the Company grows."

 

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

 

Notes to Editors

Concepta Plc

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility† in women.

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and human chorionic gonadotropin (hCG) hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future. 

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

†Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

*Ethics Committees

There are more than 80 NHS Research Ethics Committees across the UK. They exist to safeguard the rights, safety, dignity and well-being of research participants.

RECs consist of up to 15 members, a third of whom are 'lay' – their main professional interest is not in a research area, nor are they a registered healthcare professional.

RECs review research proposals and give an opinion about whether the research is ethical. They also look at issues such as the participant's involvement in the research. The committees are entirely independent of research sponsors (the organisations responsible for the management and conduct of the research), funders and the researchers themselves. This enables them to put participants at the centre of their review.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

---

1 Stability trials provide evidence on how the quality of the medical device varies with time under the influence of environmental factors, such as temperature, and are necessary for establishing a shelf life for the device and for recommended storage conditions.

 

2 A technical file is a set of documents that describes a product and can prove that the product was designed according to the requirements of a quality management system. Concepta operates under ISO13485 as its Quality Management System.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAJRMRTMBAMBAP

Close

×

RNS Number : 4689G

React Group PLC

02 March 2018

 

2 March 2018 

                                                                                React Group plc

                                               (the ''Company'' or ''React'')

                          Additional Contract win with Major London Hospital

 

REACT Group plc (AIM: REAT), the specialist provider of rapid response deep cleaning and emergency decontamination services, is pleased to announce that its subsidiary, REACT Specialist Cleaning Limited (''RSCL''), has signed an additional Service Contract with a major facilities company for the provision of deep cleaning services for the same major London hospital as the initial contract announced on 11 September 2017.

 

The Service Contract is for a period of 18 months.  It covers both deep cleaning and that RSCL has been appointed as preferred supplier for other ad hoc work.

 

RSCL has been awarded initial purchase orders totalling £206,000 (excluding VAT), for deep cleaning work under the Service Contract.  The additional provision under the Service Contract for other ad hoc services is significant.  This is because whilst there is no guarantee as to the level of additional work, REACT is now the preferred supplier and similar ad hoc services from this client contributed in excess of £250,000 to revenue in the previous financial year ended 30 September 2017.

 

Gill Leates, the Chairman said, 'We are very pleased that the company has continued to build more contract work, which reflects on the high standards that our teams continue to deliver.  We will continue our strategy of developing the business in our areas of core expertise'.

 

For further information please contact:  

 

REACT Group plc
Gill Leates – Chairman	07799 662642
SPARK Advisory Partners Limited
Neil Baldwin	0113 370 8974
Mark Brady	0113 379 8971
Whitman Howard Limited
Nick Lovering	0207 659 1224

    

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTLLFSTVLILIIT

Close

×

RNS Number : 1363G

Midatech Pharma PLC

28 February 2018

 

 

 

 

28 February 2018

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency

 

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) for its advanced liver cancer drug candidate MTD119.

 

MTD119 (previously MTR104) is a treatment for hepatocellular carcinoma (HCC), a rare, aggressive cancer that affects the liver. There are very few treatments for HCC, particularly for patients with an advanced form of the disease, and fewer than ten per cent of patients with HCC currently survive beyond five years of diagnosis. MTD119 is a combination of Midatech's gold nanoparticle (GNP) technology with the potent anti-tubulin chemotherapeutic maytansine, in which the GNP is designed to improve the biodistribution and targeted delivery of the maytansine agent to the tumour site.

 

The ODD programme provides orphan status to drugs intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 5 in 10,000 people in the EU. Sponsors who obtain ODD benefit from development assistance and are eligible for 10 years of market exclusivity once the medicine is on the market.

 

A recent pre-clinical study comparing the efficacy of MTD119 with sorafenib, the current standard of care, shows a greater response rate and suggests the potential for an improved efficacy profile for MTD119.

 

The global HCC market is estimated to be worth around $1bn by 2024 however, due to the limited efficacy and high toxicity of existing treatments, we believe there is scope to significantly expand this market.

 

This programme is currently being prepared for clinical trials MTD119 has commenced formal investigational new drug (IND) application enabling toxicology studies, with completion of the pilot studies expected in H1 2018.  This will be followed by assessment and full toxicology with an expected IND submission to the US Food and Drug Administration for first in human studies in H2 2018 – H1 2019.

 

Commenting on the news, Dr Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "We are pleased that the EMA has granted MTD119 Orphan Drug Designation to treat patients with liver cancer. Not only does this represent an important regulatory milestone for Midatech, but the decision means Midatech will receive financial and developmental support, as well as marketing exclusivity following approval of the drug. Our focus now is on advancing the development of MTD119 as fast as possible while also continuing to work on our exciting pipeline of oncology and immunotherapy assets, which contains several potentially significant and value-driving inflection points in 2018."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Ryan McCarthy

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Nick Brown

Tel: +44 (0)20 3709 5700

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected]

 

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on the research and development of a pipeline of medicines for oncology and other therapeutic areas, and marketing these through its established US commercial operation which includes four cancer care supportive products and two further co-promoted products.  Midatech's strategy is to internally develop oncology products, and to drive growth both organically and through strategic acquisitions.  The Company's R&D activities are focused on three innovative platform technologies to deliver drugs at the "right time, right place": gold nanoparticles ("GNPs") to enable targeted delivery; Q-Sphera polymer microspheres to enable sustained release ("SR") delivery; and Nano Inclusion ("NI") to provide local delivery of therapeutics, initially to the brain. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

 

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialize products for conditions using the nanoparticle and sustained release drug delivery platforms, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

RESZMGZZVNMGRZM

Close

×

RNS Number : 2927G

Altitude Group PLC

28 February 2018

 

 

 

 

 

 

ALTITUDE GROUP PLC

 (the "Company" or "Altitude")

 

NAPCO Partnership Agreement

 

Altitude Group plc (AIM: ALT), the operator of a leading marketplace for personalised products, is pleased to announce that it has signed a new two year partnership agreement with the printing, packaging and publishing division of NAPCO Media ("NAPCO"), a leading and large North American digital media, marketing and publishing company. Under the terms of the partnership agreement Altitude will provide a 'white labelled' ChannlPro platform to NAPCO that will mirror the AiMpro product.

 

The NAPCO partnership will provide Altitude with access to approximately 80,000 commercial print businesses of which approximately 12,500 are already active in the promotional product market. The white labelled ChannlPro platform will provide these businesses with easy access to the promotional product industry and as they start to transact on the platform Altitude will generate GTR based on the same revenue model that was used for AiMpro.

 

Altitude is now engaged in developing the white label ChannlPro platform for NAPCO and, once it is launched, the NAPCO offering will be able to leverage the same supplier database already partnering with Altitude on AiMpro.

 

Defined terms used in this announcement will have the same meaning (unless the context otherwise requires) as set out in the Circular posted to shareholders today which is available on the Company's website at www.altitudeplc.com. 

 

Enquiries:

 

Altitude Group plc Peter Hallett, Executive Chairman	07887 987469
finnCap ltd	020 7220 0500
Jonny Franklin-Adams (Corporate Finance)
Scott Mathieson (Corporate Finance)
Richard Chambers (Corporate broking)

 

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAQVLFLVLFBBBZ

Close

×

RNS Number : 0463G

1PM PLC

27 February 2018

 

 

27 February 2018

 

 

1pm plc

(the "Group" or the "Company")

 

1PM SECURES INTERNATIONAL PEER-TO-PEER FINTECH FUNDING CAPABILITY

Gains access to the Mintos marketplace, a leading online marketplace

for financing business loans via global retail investors;

Becomes first UK based loan originator to join Mintos;

 

1pm plc, the AIM listed independent specialist, non-bank provider of finance facilities to the UK SME sector is pleased to announce that it has entered into a Cooperation Agreement with 'AS Mintos Marketplace' ("Mintos") to be a loan originator on its market-leading online marketplace for loans.

 

Mintos is a global online marketplace for loans where retail investors can participate in many different types of loans originated by non-bank loan providers. Through Mintos, 1pm will reap the benefits of the peer-to-peer lending model in financing loans that have traditionally been funded on its own balance sheet.

 

1pm is the first loan originator from the UK to access the Mintos marketplace and joins approximately 30 other loan originators globally. By becoming a loan originator on the marketplace, 1pm is able to harness the resources of the fully developed fintech capability and to instantly reach approximately 50,000 registered retail investors across the globe for the first time, thus also creating an important new funding channel.

 

The leverage created by this new funding source will allow 1pm to increase the number of loans written through its loans division without taking on significant additional risk of default. Up to 90% of each loan originated and made available on the Mintos marketplace will be assigned to investors on a non-recourse basis. Access to the Mintos marketplace therefore creates greater lending flexibility and more growth potential than a solely balance sheet approach to lending. All business loans assigned by 1pm will be in sterling. The Cooperation Agreement starts with an initial six-month trial period.

 

Mintos' mission is to facilitate free and efficient movement of capital and since launching in 2015, it has become the world's largest marketplace of its kind (www.mintos.com).

 

Commenting on this latest initiative, Ian Smith, CEO, said:

 

"An important part of our strategic growth plan is to harness the benefits of financial technology. By joining the Mintos marketplace, we will now be able to accelerate our loans business origination without increasing risk and to access retail investors globally and efficiently, a funding source that would be unavailable to us without this digital capability".

 

For an audio interview with Ian Smith about this initiative, follow this link: http://bit.ly/1pmMintos0218

 

 

For further information, please contact:
1pm plc
Ian Smith, Chief Executive Officer	01225 474230
James Roberts, Chief Financial Officer	01225 474230
Walbrook PR	0117 985 8989
Paul Vann	07768 807631
	[email protected]

 

 

About 1pm:

 

The Company was admitted to AIM in August 2006.

 

1pm plc is a group of established independent finance companies focused on providing SMEs with accessible funding to add value to their businesses. All customers must have good credit histories and proven ability to repay their finance commitments.

 

Mission Statement – 'Helping the UK economy grow by supporting SMEs'

 

More information is available on the Company website www.1pm.co.uk

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAUBONRWVAUURR

Close

×

RNS Number : 8396F

Falcon Media House Limited

26 February 2018

 

                                                                                                               

 

Falcon Media House Expands Live Streaming to India in Deal with JPR Network

 

·     Landmark agreement shows Indian cable operator JPR Network diversifying to deliver TV via mobile

·     On-demand streaming enables subscriber growth at fraction of the cost of cable or satellite

·     Deal marks Falcon's expansion into India, after concluding agreements in Nigeria, South Africa, Canada and Mongolia

 

26th February 2018 (London, Mumbai) – Falcon Media House Plc, the London Stock Exchange-listed digital technology and media group, today announces that it has agreed to provide live and on demand digital streaming technology to JPR Network, the Mumbai-based cable network provider.

 

The deal extends Falcon's global footprint to India, the world's fastest growing market for mobile subscribers, following agreements in Nigeria, South Africa, Canada and Mongolia. JPR Network benefits from a partnership in which Falcon provides subsidiary Quiptel's patented Q-Flow open Internet streaming technology, also known as over-the-top (OTT), and Mumbai-based Media Nucleus provides systems integration.

 

"We're looking forward to delivering the first of many such systems as OTT platforms represent the future of broadcasting," comments Falcon Media House Executive Chairman, Gert Rieder. "Local networks and mobile services in India, Africa and Southeast Asia are not always reliable enough to provide high quality streaming experiences – which is where the Quiptel technology makes a big difference."

 

Going beyond traditional network limitations, Q-Flow overcomes the challenges of congested and slow connections to deliver content to the end consumer using the most efficient and cost-effective route, resulting in seamless streaming over even the most challenging networks and mobile conditions. Rather than investing in hardware and laying new network cables, Q-Flow enables broadcasters and cable companies to increase customers with a lower capital expenditure, creating a unique win: win solution for both the OTT operator and their end users alike.

 

The solution is particularly applicable to India, where the number of mobile subscribers is projected to soar by 310 million between 2016 and 2020, almost double the increase in China and beating every other country worldwide, according to GSMA Intelligence.

 

TV network providers like JPR Network are taking advantage by offering content through OTT at a fraction of the infrastructure set-up cost for traditional cable, typically in the region of US$ 600-1,000 per home. Q-Flow additionally enables JPR Network to increase penetration with its existing 150,000-plus subscribers by streaming content to their mobiles and other devices, while also extending reach beyond its physical geography of Mumbai or even India. Under its agreement with the Falcon and Media Nucleus partnership, JPR Network will pay an undisclosed base plus a fee per subscriber.

 

The partnership between Falcon and Media Nucleus targets medium and large size broadcasters with a potential reach of 250 million users in India and the partners have already identified over 200 such companies across the region. Beyond India, Media Nucleus also provides innovative broadcast and Pay TV services to clients ranging from Fox Movies in the Middle East to Zuku in East Africa and now they have added the Falcon OTT solution to their portfolio.

 

Falcon Media House Executive Chairman, Gert Rieder:

 "Having a presence in India is key for success and with our strategic partner Media Nucleus we can provide local support and implementation to enable a timely cost-effective solution to other MSOs looking to provide value added services to their existing subscribers. Media Nucleus has a huge established customer base including many of the leading broadcast companies in India. Together we already have an immediate pipeline of MSOs who represent over 2 million subscribers and we are looking forward to enabling them to deliver a world class OTT service using Q-Flow that will help them to grow in a cost-efficient manner, avoiding the huge costs of building infrastructure."

Santosh Nair, Co-Founder and Director Media Nucleus:

"Media Nucleus is at the heart of India's burgeoning technology industry and has over 3 decades of Software experience in the DVB sector with a deep knowledge-base, benchmarked by Industry experts in handshake technology protocols, enabling integrated multi product platform deployments.

 

With a seamless and robust single platform window, Quiptels unique architecture enables service and content providers alike to transparently adhere to all Audit authority statutory requirements".

 

"The explosion of the smartphone market, and with it the increase in demand for streaming video content, requires a robust and reliable OTT service both inside and outside the home. For today's customers it's essential that the quality of experience can be relied upon. Falcon Media House represents the future of the industry, with Quiptel's revolutionary Q-Flow technology and a deep understanding of global consumer needs. The combined strength of both companies' products offers a tailored solution to the MSOs and we look forward to announcing more wins in the very near future."

ENDS

 

More information available at www.falconmediahouse.com

Contact: [email protected]

About Falcon Media House

Falcon Media House (LSE:FAL) is a multi-divisional, global internet media group. We are building a new breed of media entertainment house for the way people want to consume live and on-demand video content. Our goal is to create an ecosystem where great technology meets great entertainment ideas and finds the right audience. The Group is capitalising on explosive demand for digital video, streamed "live" and "on-demand" known as the Over-The-Top (OTT) video streaming market. OTT solutions are powered by Quiptel's innovative patented technology enabling "intelligent streaming" (aka Q-Flow) on any network to any device, dramatically improving QoS and QoE and 'bridging the last mile'.

 

About Media Nucleus

Media Nucleus is at the heart of India's burgeoning Media Services technology industry and has been built client relationships lasting over a decade across Asia and Africa.

Catering to Broadcasters and Digital Cable companies – by empowering their offering with seamless integration and encryption services – Media Nucleus has established itself in a niche domain.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTBLGDDDDDBGIX

Close